Puma Biotech (PBYI) Tops Q3 EPS by 113c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. ADYEN:NA
8. ADYYF
9. WDAY
10. DVLT

Go back to Puma Biotech (PBYI) Tops Q3 EPS by 113c

Puma Biotech (PBYI) PT Raised to $122 at Barclays on 3Q Report; 'Nerlynx Initial Launch Trend Encouraging, EU Decision in 1Q18'

November 10, 2017 1:10 PM EST

Barclays raised its price target on Puma Biotech (NASDAQ: PBYI) to $122.00 (from $103.00) while maintaining a Overweight rating, following the company's third quarter earnings report.

Analyst Gena Wang notes a positive outlook on the shares, as the company reported third quarter earnings per share and... More

Puma Biotechnology (PBYI) PT Raised to $142 at Credit Suisse, 'Early Trend Indicators Stronger Trajectory'

November 10, 2017 4:56 AM EST

Credit Suisse raised its price target on Puma Biotechnology (NASDAQ: PBYI) to $142.00 (from $136.00) while maintaining a Outperform rating.

Analyst Alethia Young models Nerlynx Q4 and 2018 sales at $28 million and $214 million respectively. The analyst believes the selloff following Thursday's report was due to high... More

Puma Biotechnology (PBYI) PT Raised to $164 at Citi, 'Buy The Dip'

November 10, 2017 4:14 AM EST

Citi raised its price target on Puma Biotechnology (NASDAQ: PBYI) to $164.00 (from $156.00) while maintaining a Buy rating.

Analyst Yigal Nochomovitz believes investors should buy the dip noting early metrics are looking very good even without the benefit of EAP and modest discontinuations. The... More